DE4023134C2 - Verfahren zur Herstellung einer pharmazeutischen Zubereitung in Form von Mikropartikeln - Google Patents

Verfahren zur Herstellung einer pharmazeutischen Zubereitung in Form von Mikropartikeln

Info

Publication number
DE4023134C2
DE4023134C2 DE4023134A DE4023134A DE4023134C2 DE 4023134 C2 DE4023134 C2 DE 4023134C2 DE 4023134 A DE4023134 A DE 4023134A DE 4023134 A DE4023134 A DE 4023134A DE 4023134 C2 DE4023134 C2 DE 4023134C2
Authority
DE
Germany
Prior art keywords
microparticles
copolymer
indicates
lactic acid
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE4023134A
Other languages
German (de)
English (en)
Other versions
DE4023134A1 (de
Inventor
Piero Dr Orsolini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debio Recherche Pharmaceutique SA
Original Assignee
Debiopharm SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm SA filed Critical Debiopharm SA
Publication of DE4023134A1 publication Critical patent/DE4023134A1/de
Application granted granted Critical
Publication of DE4023134C2 publication Critical patent/DE4023134C2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE4023134A 1989-07-28 1990-07-20 Verfahren zur Herstellung einer pharmazeutischen Zubereitung in Form von Mikropartikeln Expired - Lifetime DE4023134C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH2829/89A CH679207A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-07-28 1989-07-28

Publications (2)

Publication Number Publication Date
DE4023134A1 DE4023134A1 (de) 1991-01-31
DE4023134C2 true DE4023134C2 (de) 1997-04-17

Family

ID=4242536

Family Applications (1)

Application Number Title Priority Date Filing Date
DE4023134A Expired - Lifetime DE4023134C2 (de) 1989-07-28 1990-07-20 Verfahren zur Herstellung einer pharmazeutischen Zubereitung in Form von Mikropartikeln

Country Status (23)

Country Link
US (1) US5134122A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH0662427B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT397197B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU619996B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE1003093A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2021767C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH679207A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE4023134C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK175495B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2020890A6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI97688C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2650182B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2234169B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR1001215B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE65397B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL95120A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1243357B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU87772A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL194858C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO300304B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT94842B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE504279C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA905654B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2103994C1 (ru) * 1991-07-22 1998-02-10 Аста Медика Аг Композиция в форме микросфер для пролонгированного и контролируемого высвобождения пептидного лекарственного вещества

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
CH681425A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-11-14 1993-03-31 Debio Rech Pharma Sa
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
DK0528978T3 (da) * 1990-05-16 2003-02-17 Southern Res Inst Mikrokapsler til reguleret afgivelse og deres anvendelse i stimulering af nervefibervækst
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
CA2178592C (en) * 1993-12-09 2009-07-28 Jurgen Engel Long-acting injection suspensions and a process for their preparation
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
US5569468A (en) * 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
FR2748205A1 (fr) 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
AU4571097A (en) * 1996-10-09 1998-05-05 Takeda Chemical Industries Ltd. A method for producing a microparticle
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
AU1384199A (en) 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
EA004502B1 (ru) * 1998-12-16 2004-04-29 Авентис Фармасьютикалз Инк. Фармацевтическая композиция антагониста рецептора серотонина и способ ее получения
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
CA2689696C (en) 1999-02-26 2013-08-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
ES2169980B1 (es) 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
US6362308B1 (en) 2000-08-10 2002-03-26 Alkermes Controlled Therapeutics Inc. Ii Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
JP2004536799A (ja) * 2001-04-26 2004-12-09 コントロール・デリバリー・システムズ・インコーポレイテッド コドラッグを含有する持続的放出用ドラッグデリバリーシステム
SK14182003A3 (sk) * 2001-05-23 2004-05-04 Hexal Ag Homogenizát pre implantáty a mikročastice
AU2002324447B2 (en) 2001-06-22 2006-06-29 Durect Corporation Zero-order prolonged release coaxial implants
IN2014DN10834A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2001-09-17 2015-09-04 Psivida Inc
PT1532985T (pt) * 2002-06-25 2017-01-20 Takeda Pharmaceuticals Co Processo de produção de uma composição de libertação sustentada
SI1594517T1 (sl) 2003-01-28 2007-10-31 Microbia Inc Sestavki za zdravljenje gastrointestinalnih motenj
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
JP2006525306A (ja) * 2003-04-30 2006-11-09 デビオファーム ソシエテ アノニム ゴナドトロピン・ホルモン放出ホルモンを使用する方法及び組成物
WO2005020933A2 (en) * 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
CN105820160B (zh) 2003-11-05 2019-02-12 萨可德生物科学公司 细胞粘着调节剂
WO2005063276A1 (en) * 2003-12-23 2005-07-14 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone
FR2865938B1 (fr) * 2004-02-05 2006-06-02 Sod Conseils Rech Applic Formulation retard solide comprenant de l'acetate de triptoreline
AU2005325213B2 (en) 2004-08-04 2010-10-07 Evonik Operations Gmbh Methods for manufacturing delivery devices and devices thereof
WO2006026731A1 (en) * 2004-08-30 2006-03-09 Spineovations, Inc. Method of treating spinal internal disk derangement
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
EP3195861A1 (en) 2005-05-17 2017-07-26 SARcode Bioscience Inc. Compositions and methods for treatment of dry eye disorders
KR100722607B1 (ko) * 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US10166181B2 (en) * 2007-06-06 2019-01-01 Debiopharm Research & Manufacturing Sa Slow release pharmaceutical composition made of microgranules
CA2958665C (en) 2007-10-19 2021-03-02 Sarcode Bioscience Inc. Compositions and methods for treatment of diabetic retinopathy
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US8469961B2 (en) * 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
US20100010549A1 (en) * 2008-03-05 2010-01-14 Neville Alleyne device and method of minimally invasive extracapsular ligamentous augmentation for canine stifle ligament injuries
US8080562B2 (en) * 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US20090258069A1 (en) * 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010123563A2 (en) * 2009-04-23 2010-10-28 Sustained Nano Systems Llc Controlled release dispensing device
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR101411349B1 (ko) 2010-12-24 2014-06-25 주식회사 삼양바이오팜 생리활성 펩타이드를 포함하는 마이크로입자 및 그의 제조방법, 및 그를 포함하는 약제학적 조성물
WO2012151343A1 (en) 2011-05-04 2012-11-08 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
EP2630964A1 (en) 2012-02-22 2013-08-28 Immundiagnostik AG Method and medicament for treating patients in risk of prediabetes and type-2 diabetes
PT2851085T (pt) 2012-05-14 2019-10-11 Teijin Pharma Ltd Composição proteica esterilizada por radiação
JP6607780B2 (ja) 2012-07-25 2019-11-20 サルコード・バイオサイエンス・インコーポレイテッド Ｌｆａ−１阻害剤およびその多形
HK1218629A1 (zh) 2013-02-25 2017-03-03 Bausch Health Ireland Limited 用於结肠清洁的鸟苷酸环化酶受体激动剂
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
CN105792838A (zh) * 2013-10-08 2016-07-20 辉凌公司 通过pgss制备的包含gnrh的微粒
EP3054969B1 (en) 2013-10-10 2021-03-10 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
SG11201705620TA (en) 2015-01-16 2017-08-30 Spineovations Inc Method of treating spinal disk
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis
MX2020000376A (es) 2017-07-11 2020-07-14 Sustained Nano Systems Llc Formulaciones farmaceuticas hipercomprimidas.
CA3069155A1 (en) 2017-07-11 2019-01-17 Sustained Nano Systems Llc Radiation sterilization of hypercompressed polymer dosage forms
JOP20200068A1 (ar) 2017-09-26 2020-04-27 Nanomi B V طريقة لتحضير جسيمات دقيقة بواسطة تقنية مستحلب مزدوج
WO2021185373A1 (zh) * 2020-03-20 2021-09-23 苏州医本生命科技有限公司 载药用微粒、载药微粒、蓄粒管及其植入系统
US12318508B2 (en) 2023-06-02 2025-06-03 33 Medical, Inc. Compositions for treatment of discogenic pain, and processes for making and using the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US3978203A (en) * 1974-07-12 1976-08-31 Dynatech Corporation Sustained release of pharmaceuticals from polyester matrices
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
US4483807A (en) * 1981-01-27 1984-11-20 Japan Atomic Energy Research Institute Process for producing a slow release composite
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60181029A (ja) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
IL79134A (en) * 1985-07-29 1991-06-10 American Cyanamid Co Continuous release peptide implants for parenteral administration
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JPS63218632A (ja) * 1987-03-06 1988-09-12 Japan Atom Energy Res Inst ホルモンに徐放性機能を付与した生体分解型コポリ（グルコ−ル酸／ｌ−乳酸）複合体の製造方法
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2103994C1 (ru) * 1991-07-22 1998-02-10 Аста Медика Аг Композиция в форме микросфер для пролонгированного и контролируемого высвобождения пептидного лекарственного вещества

Also Published As

Publication number Publication date
ZA905654B (en) 1991-05-29
BE1003093A3 (fr) 1991-11-19
JPH0662427B2 (ja) 1994-08-17
GR1001215B (el) 1993-06-21
PT94842B (pt) 1997-04-30
IL95120A0 (en) 1991-06-10
DK175495B1 (da) 2004-11-08
NL9001646A (nl) 1991-02-18
NL194858B (nl) 2003-01-06
GB2234169A (en) 1991-01-30
IL95120A (en) 1994-10-07
CA2021767A1 (en) 1991-01-29
CH679207A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-01-15
FI903643A0 (fi) 1990-07-19
IT1243357B (it) 1994-06-10
IE65397B1 (en) 1995-10-18
FI97688B (fi) 1996-10-31
SE504279C2 (sv) 1996-12-23
DK180790D0 (da) 1990-07-27
CA2021767C (en) 1996-10-22
GR900100568A (en) 1991-12-10
SE9002522L (sv) 1991-01-29
AU619996B2 (en) 1992-02-06
NO903264L (no) 1991-01-29
FI97688C (fi) 1997-02-10
US5134122A (en) 1992-07-28
FR2650182B1 (fr) 1992-05-15
ATA154590A (de) 1993-07-15
ES2020890A6 (es) 1991-10-01
NL194858C (nl) 2003-05-06
AT397197B (de) 1994-02-25
AU5910390A (en) 1991-01-31
SE9002522D0 (sv) 1990-07-27
JPH0366625A (ja) 1991-03-22
FR2650182A1 (fr) 1991-02-01
DE4023134A1 (de) 1991-01-31
DK180790A (da) 1991-01-29
IT9021019A1 (it) 1992-01-23
NO300304B1 (no) 1997-05-12
IT9021019A0 (it) 1990-07-23
GB2234169B (en) 1993-02-10
GB9015722D0 (en) 1990-09-05
PT94842A (pt) 1991-03-20
LU87772A1 (fr) 1990-12-11
IE902592A1 (en) 1991-02-27
NO903264D0 (no) 1990-07-23

Similar Documents

Publication Publication Date Title
DE4023134C2 (de) Verfahren zur Herstellung einer pharmazeutischen Zubereitung in Form von Mikropartikeln
DE69728371T2 (de) Verfahren zur herstellung von implantaten, die leuprolid enthalten
DE3822459C2 (de) Pharmazeutische Zusammensetzung
DE69828252T2 (de) Zusammensetzung mit verzögerter freisetzung, wobei medikamente in mikropartikel aus hyaluronsäure eingekapselt sind
US5439688A (en) Process for preparing a pharmaceutical composition
DE69312947T2 (de) Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe
DE69317306T2 (de) Verfahren zur herstellung von pharmazeutische zusammensetzungen mittels ultraschall
US5225205A (en) Pharmaceutical composition in the form of microparticles
DE60027272T2 (de) Stabile, nichtwässrige, einphasige, biokompatible, viskose Träger und Formulierungen, die diese Träger verwenden
DE69306755T2 (de) Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
DE3850823T3 (de) System zur Freisetzung von Medikamenten und dessen Herstellungsmethode.
DE69327491T2 (de) Verfahren zum Herstellen von Microkugeln für die verzögerte Verabreichung des LHRH-Hormons und dessen Analoga, Microkugeln und so erhaltene Zusammensetzungen
DE69714448T2 (de) Verfahren zur herstellung von präparaten mit kontrollierter wirkstofffreisetzung auf basis von polymeren
DE3783958T3 (de) Verzögerte Abgabe von makromolekularen Polypeptiden.
DE3688213T2 (de) Polymer, seine herstellung und verwendung.
AT408609B (de) Zubereitung zur stetigen und kontrollierten abgabe von medikamentösen substanzen und verfahren zu deren herstellung
DE69426196T2 (de) Verfahren zur Herstellung eines biologisch abbaubaren Materials für die verzögerte Freisetzung eines Medikaments und mit diesem Verfahren hergestelltes Material
DE69009743T2 (de) Dosierungsform für dauerverabreichung.
DE69103104T2 (de) Mikrokugeln aus denen wasserlösliche materialien mit vorbestimmter geschwindigkeit freigesetzt werden, und verfahren zur herstellung derselben.
DE3886772T2 (de) Eine arzneimittelkomposition mit mikrosphären und ihr herstellungsverfahren.
DE69719367T2 (de) Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
DE69332210T2 (de) Biologisch abbaubares, schmelzgesponnenes abgabesystem zur kontrollierten freisetzung
DE69811710T2 (de) Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung
EP0202445A2 (de) Cytostatikhaltiges Pharmakadepot
DE4031881A1 (de) Loesungsmittelfreie, oral zu verabreichende pharmazeutische zubereitung mit verzoegerter wirkstoffreisetzung und verfahren zu deren herstellung

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: DEBIO RECHERCHE PHARMACEUTIQUE S.A., MARTIGNY, CH

8328 Change in the person/name/address of the agent

Representative=s name: WESTENDORP SOMMER, 80336 MUENCHEN